,Chi-Square p-value
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,0.48986531740055594
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,1.0
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,0.6673225668318831
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,0.9848942086344845
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,1.0
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,0.4514579085201703
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,0.18442424725409384
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,0.17661718662452705
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,0.12629815240453887
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,1.0
A High-Content qHTS Against Drug Library for the Identification of Small Molecules that Inhibit DYT1 Early Onset Primary Dystonia-Associated Cell Pathology,0.18377310058406726
A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,0.3762343083344285
A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,0.7119231506921899
A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,0.17756877681093802
A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,0.015781416456707793
A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,0.49480261572680917
A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,0.19472154196248764
Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,0.11847155151828737
Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),0.1861198627260326
Acetylcholinesterase (AChE) small molecule antagonists: colormetric cell-based qHTS assay,1.0
Acetylcholinesterase (AChE) small molecule antagonists: enzyme-based qHTS assay,0.7744468868260557
Acetylcholinesterase (AChE) small molecule antagonists: fluorescence cell-based qHTS assay,0.5191499867907746
Agonist activity at human ADRA1A in an in vitro cell-based assay (CRO assay) measured by fluorescence spectroscopy,1.0
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,1.0
Antagonist activity at human ADRA1A in an in vitro cell-based assay measured by fluorescence spectroscopy,1.0
Antagonist activity at human TBXA2R in an in vitro cell-based assay measured by fluorescence spectroscopy,1.0
Antagonist activity human CHRM1 in an in vitro cell-based assay measured by fluorescence spectroscopy,1.0
Antagonist of Human D 1 Dopamine Receptor: qHTS,0.7669751036964281
Binding affinity towards human ADORA3 (agonistic activity) in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human ADRA2A in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human AR in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human CHRM2 in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human DRD1 in an in vitro assay with cellular components (NIBR assay) measured by scintillation counting,1.0
Binding affinity towards human DRD3 in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human ESR1 in an in vitro cell free assay (CRO assay) measured by membrane filtration,1.0
Binding affinity towards human HRH3 in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human HTR1A in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human OPRM1 in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human PGR in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human SLC6A2 in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human SLC6A3 in an in vitro assay with cellular components measured by scintillation counting,1.0
Binding affinity towards human SLC6A4 in an in vitro assay with cellular components measured by scintillation counting,1.0
Biochemical firefly luciferase enzyme assay for NPC,0.34554651177820417
"CYP3A4 induction through human pregnane X receptor (PXR) by small molecules, qHTS assay",0.5506708737927524
"Caspase-3/7 induction in CHO-K1 cells by small molecules, qHTS assay: Summary",1.0
"Caspase-3/7 induction in CHO-K1 cells by small molecules, qHTS cell viability counter screen",0.00631548224613162
"Caspase-3/7 induction in HepG2 cells by small molecules, qHTS assay",0.38988739348765444
"Caspase-3/7 induction in HepG2 cells by small molecules, qHTS assay: Summary",0.02607521522346847
"Caspase-3/7 induction in HepG2 cells by small molecules, qHTS cell viability counter screen",0.12418046413014192
Cell-based high throughput primary assay to identify activators of GPR151,0.6193452946244169
Compound was evaluated for inhibition of human ACHE in an vitro cell free assay measured by absorbance method,1.0
"Compound was evaluated for inhibition of human KCNH2 in an in vitro assay with cellular components measured by membrane filtration, radioactivity method",1.0
Compound was evaluated for inhibition of human MAOA in an in vitro cell free assay measured by fluorescence spectroscopy,1.0
Compound was evaluated for inhibition of human PDE3A in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Compound was evaluated for inhibition of human PDE4A in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Compound was evaluated for inhibition of human PTGS1 in an in vitro cell free assay measured by fluorescence method,1.0
Compound was evaluated for inhibition of human PTGS1 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,0.09620481968080305
Cytochrome P450 Family 1 Subfamily A Member 2 (CYP1A2) small molecule antagonists: luciferase reporter qHTS assay,0.0053217062686617455
Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) small molecule antagonists: luciferase reporter qHTS assay,0.02780776789040305
Cytochrome P450 Family 2 Subfamily C Member 9 (CYP2C9) small molecule antagonists: luciferase reporter qHTS assay,0.0005275386941242678
Cytochrome P450 Family 2 Subfamily D Member 6 (CYP2D6) small molecule antagonists: luciferase reporter qHTS assay,0.19564036949072952
Cytochrome P450 Family 3 Subfamily A Member 4 (CYP3A4) small molecule antagonists: luciferase reporter qHTS assay,0.01252177112262955
Cytochrome P450 family 2 subfamily C member 9 (CYP2C9) small molecule antagonists: luciferase cell-based qHTS assay,0.00014765457080025712
Cytochrome P450 family 2 subfamily D member 6 (CYP2D6) small molecule antagonists: luciferase cell-based qHTS assay,0.7459652485210388
Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) small molecule antagonists: luciferase cell-based qHTS assay,0.007172873852438806
Cytochrome P450 family 3 subfamily A member 7 (CYP3A7) small molecule antagonists: luciferase cell-based qHTS assay,2.9947390228317666e-05
Cytochrome panel assay with activity outcomes,0.545679034628733
Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening,0.4324370199173643
Cytotoxicity counterscreen for inhibitors of SARS-CoV-2 cell entry,0.11356209541437738
DLD viability from Cell TiterGlo-screen,0.08575044808018291
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,1.0
Dicer-mediated maturation of pre-microRNA,0.9188682658058104
Drug repurposing screens with cells derived from glioblastoma tumor samples,0.42217331808842684
ERK5 transcriptional activity HTS,1.0
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),0.42062986994127316
"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",0.8199928687044394
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),0.3590523077270902
"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",0.5335130509555259
"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",0.2842379658976638
GLP1 secretion from NCI-H716 cells-screen,0.2610520805691837
GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,0.09355500146688432
HCT116 viability from Cell TiterGlo-screen,0.10478939566140827
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,0.5603586807002439
HTS Assay for Peg3 Promoter Inhibitors,0.6346510340581906
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,0.09465603672625576
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,0.9441332245261623
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,0.046050755862323454
High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,0.08271714992990331
High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,0.1864523783782732
Human Ether-a-go-go-Related Gene (hERG) channel small molecule antagonists: fluorescence cell-based qHTS assay,0.539328325420237
"Human gonadotropin-releasing hormone receptor (GnRHR) small molecule agonists, calcium flux assay in GnRHR-HEK293 cells",0.432198424893272
"Human pregnane X receptor (PXR) activation by small molecules, qHTS assay",1.0
"Human pregnane X receptor (PXR) small molecule agonists, qHTS assay",0.5407224550402866
"Human pregnane X receptor (PXR) small molecule agonists, qHTS cell viability counter screen",0.257954503337411
Human pregnane X receptor (PXR) small molecule agonists: Summary,0.083304527317806
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,0.6301812939620496
In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,0.8328846367766345
Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method,1.0
Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,0.9573744392503091
Inhibitors of USP1/UAF1: Pilot qHTS,0.3325063124362838
Inhibitors of the vitamin D receptor (VDR): qHTS,0.25885219738673426
Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,0.9553139337596412
Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,1.0
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.,0.5809540925917628
MELAS cybrid survival enhancement under low glucose conditions,1.0
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,0.6912827986828021
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,0.15424665126018686
NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,0.9956397044093369
NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,0.31459790499802703
NCI Yeast Anticancer Drug Screen. Data for the mec2 strain,0.2861008658893074
NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,0.5129798265856874
NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,0.3675959352845628
NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,0.7426420532943128
"NCI human tumor cell line growth inhibition assay. Data for the 786-0 Non-Small Cell Lung cell line, single concentration",0.4825835795357212
"NCI human tumor cell line growth inhibition assay. Data for the A498 Non-Small Cell Lung cell line, single concentration",0.8680938952188777
"NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line, single concentration",0.5575957539679344
"NCI human tumor cell line growth inhibition assay. Data for the ACHN Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the BT-549 Non-Small Cell Lung cell line, single concentration",0.11035133646739059
"NCI human tumor cell line growth inhibition assay. Data for the CAKI Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Non-Small Cell Lung cell line, single concentration",0.3835332858218723
"NCI human tumor cell line growth inhibition assay. Data for the DU45 Non-Small Cell Lung cell line, single concentration",0.5128775027580301
"NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Non-Small Cell Lung cell line, single concentration",0.9307233906432747
"NCI human tumor cell line growth inhibition assay. Data for the HCT16 Non-Small Cell Lung cell line, single concentration",0.22442940311238993
"NCI human tumor cell line growth inhibition assay. Data for the HCT5 Non-Small Cell Lung cell line, single concentration",0.4946396572470009
"NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Non-Small Cell Lung cell line, single concentration",0.11131858099989447
"NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line, single concentration",0.9007834650797255
"NCI human tumor cell line growth inhibition assay. Data for the HS 578T Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the HT29 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Non-Small Cell Lung cell line, single concentration",0.2339346435486021
"NCI human tumor cell line growth inhibition assay. Data for the K-562 Non-Small Cell Lung cell line, single concentration",0.6685598667063721
"NCI human tumor cell line growth inhibition assay. Data for the KM12 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Non-Small Cell Lung cell line, single concentration",0.8741268888604162
"NCI human tumor cell line growth inhibition assay. Data for the M14 Non-Small Cell Lung cell line, single concentration",0.94029633754008
"NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Non-Small Cell Lung cell line, single concentration",0.37712840110926293
"NCI human tumor cell line growth inhibition assay. Data for the MCF7 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Non-Small Cell Lung cell line, single concentration",0.88335723406584
"NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Non-Small Cell Lung cell line, single concentration",0.9427022384606947
"NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Non-Small Cell Lung cell line, single concentration",0.19481688914829334
"NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line, single concentration",0.7604455635093521
"NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line, single concentration",0.5582802871027306
"NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line, single concentration",0.8030594142948038
"NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Non-Small Cell Lung cell line, single concentration",0.3862246498897317
"NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the PC-3 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the SF-295 Non-Small Cell Lung cell line, single concentration",0.318864403997245
"NCI human tumor cell line growth inhibition assay. Data for the SF-539 Non-Small Cell Lung cell line, single concentration",0.8265519737426118
"NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Non-Small Cell Lung cell line, single concentration",0.8065299232137365
"NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Non-Small Cell Lung cell line, single concentration",0.6254482857810402
"NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Non-Small Cell Lung cell line, single concentration",0.6335981112713905
"NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Non-Small Cell Lung cell line, single concentration",0.631171649276106
"NCI human tumor cell line growth inhibition assay. Data for the SR Non-Small Cell Lung cell line, single concentration",0.9355234648086412
"NCI human tumor cell line growth inhibition assay. Data for the SW-620 Non-Small Cell Lung cell line, single concentration",0.9794974035485416
"NCI human tumor cell line growth inhibition assay. Data for the T-47D Non-Small Cell Lung cell line, single concentration",0.8573663496982697
"NCI human tumor cell line growth inhibition assay. Data for the TK0 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the U251 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Non-Small Cell Lung cell line, single concentration",0.9254340616043202
"NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Non-Small Cell Lung cell line, single concentration",1.0
"NCI human tumor cell line growth inhibition assay. Data for the UO-31 Non-Small Cell Lung cell line, single concentration",0.8737660647795915
NS1 protein of Zika virus - qHTS assay to identify small molecule inhibitors in human HEK 293 cells,1.0
Nrf2 qHTS screen for inhibitors,0.08349401723562322
"Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists, luciferase reporter gene qHTS assay in human keratinocytes: Summary",0.6608419304971089
Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists: luciferase reporter gene qHTS assay in human keratinocytes,0.6533029560764378
Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists: qHTS cell viability counter screen in human keratinocytes,0.4063567746973239
"P-glycoprotein substrates identified in KB-3 adenocarcinoma cell line, qHTS therapeutic library screen",0.3784654901808763
"P-glycoprotein substrates identified in KB-8-51 adenocarcinoma cell line, qHTS therapeutic library screen",0.3747799116886791
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),1.0
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),0.7426029602141121
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),0.6744381428180644
Primary qHTS Assay for Inhibitors of Recombinant Selenoprotein Glutathione Peroxidase 1 (GPX1),0.2584359319356846
Primary qHTS Assay for Inhibitors of Recombinant Selenoprotein Glutathione Peroxidase 4 (GPX4),0.3306106095741978
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2),1.0
Primary qHTS for Inhibitors of ATXN expression,0.49562395646559
Primary qHTS for Inhibitors of N-terminal methyltransferase 1 (NTMT1): MTaseGlo Assay,0.43384209903750026
"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",0.6209138781044263
"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",1.0
Primary qHTS for inhibitors of MERS-S pseudo-typed particle cell entry,0.8407830515782406
Primary qHTS for inhibitors of SARS-S pseudo-typed particle cell entry,1.0
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an RCH-ACV wild type WT cells (2C),0.1132203385927541
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an isogenic RCH-ACV NSD2 p.E1099K mutant (9B),0.03492213636028697
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compounds,0.1003064614164293
Primary qHTS to identify inhibitors of SARS-CoV-2 cell entry,0.43576359907753404
Primary screen GU AMC qHTS for Zika virus inhibitors,0.4403386266858986
"Progesterone receptor (PR) small molecule agonists, qHTS assay: Summary",1.0
"Progesterone receptor (PR) small molecule antagonists, qHTS assay: Summary",0.06338071339812743
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,1.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),1.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),1.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),1.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),1.0
"Rat pregnane X receptor (rPXR) activation by small molecules, qHTS assay",0.989764419945917
S16 Schwann cell PMP22 intronic element beta-lactamase assay,0.8160616848363217
S16 Schwann cell PMP22 intronic element firefly luciferase assay,0.8658224976684087
S16 Schwann cell viability assay (CellTiter-Glo assay),0.9949902937092765
SW480 viability from Cell TiterGlo-screen,0.08775122770153593
Screen for inhibitors of RMI FANCM (MM2) intereaction,0.9941889962784248
"TGF-beta/Smad small molecule antagonists, qHTS assay: Summary",0.7535811336359809
"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",0.22144395983603066
Toxoplasma gondii HTS in the absence of IFN-y,0.12975087498960872
Toxoplasma gondii inhibition HTS in the presence of IFN-y,0.00577676886325286
VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,0.14489198913526521
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,0.5648440834469306
Validation qHTS for antagonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2),0.844842178787725
Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression,0.29018834735983673
insulin secretion from INSE cells in the presence of 5 mM glucose-screen,1.0
mouse cGAS RapidFire screen,0.4926684001739139
nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,0.27564424319711645
p450-cyp1a2,0.22332465591512934
"p53 small molecule agonists, cell-based qHTS assay",0.053103722844026646
"p53 small molecule agonists, cell-based qHTS assay with human liver microsomes: qHTS cell viability counter screen",1.0
"p53 small molecule agonists, cell-based qHTS assay with rat liver microsomes: qHTS cell viability counter screen",0.8482464228269829
"p53 small molecule agonists, cell-based qHTS assay: Summary",0.150835572940108
"p53 small molecule agonists, cell-based qHTS assay: qHTS cell viability counter screen",0.7091961543948784
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,0.6808851454366402
qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,0.587410150590924
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",0.42435700792235653
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",0.4195188996738759
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",0.6858914361781168
qHTS Assay for Identifying Gametocytocidal Compounds,1.0
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,1.0
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,0.42023815522552455
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,0.09753189658324017
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,0.6787079631381037
qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),0.7334980302928518
qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),1.0
qHTS Assay for Inhibitors of BAZ2B,0.056522515862760296
qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),0.957896311956607
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),0.5224216299022384
"qHTS Assay for Inhibitors of Fructose,6-bisphosphate Aldolase from Giardia Lamblia",0.2727206729982559
qHTS Assay for Inhibitors of GCN5L2,0.0816701661489192
"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",1.0
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),0.010685506633947274
"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",0.983591399898346
qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),0.39437898668667015
qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,0.8025020570462421
qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,0.7589460182214683
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,0.47580540728555654
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),0.04134717981358293
qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),0.07500510417888369
qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,0.27517750180364986
qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,0.9727762168041119
qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,1.0
qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),0.32477881223647853
qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,0.25307507188160283
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,0.6652856584142843
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,1.0
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,0.47472318008363423
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,0.12116792405806119
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,0.07918727650498421
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,0.8349613943156177
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,0.866307791071679
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,0.5855179319277836
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,0.6119972097662509
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,0.2932394107780235
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,0.83621583743017
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,0.7713791212356754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,0.7051198915554275
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1,0.5322060521836143
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3,1.0
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,0.3306417756025561
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,0.30115997504806735
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,0.7212667209686545
qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,1.0
qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,0.07277347331833103
qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,0.05872162313374922
qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,0.5514196891601781
qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,0.010113258501481334
qHTS assay for small molecule agonists of the p53 signaling pathway,0.18615666845979578
qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,0.21188960502116938
qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,0.1609737465800525
qHTS assay for small molecule disruptors of the mitochondrial membrane potential,0.055941996241138714
qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,0.03572708319440621
qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,0.04868574160722289
qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,1.0
qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,0.6241609464457893
qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,0.9872926339741457
qHTS assay to identify aromatase inhibitors,1.0
qHTS assay to identify aromatase inhibitors - cell viability counter screen,0.17773946951077788
qHTS assay to identify aromatase inhibitors: Summary,0.430745787878249
qHTS assay to identify novel small-molecules to repurpose for Merkel cell carcinoma treatment,0.11731672024587529
qHTS assay to identify small molecule HDAC inhibitors,0.8805696923315778
qHTS assay to identify small molecule HDAC inhibitors: Summary,0.5361076981585546
qHTS assay to identify small molecule agonists of H2AX,0.4387036216370599
qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,0.5810764740123054
qHTS assay to identify small molecule agonists of H2AX: Summary,0.06290331665181559
qHTS assay to identify small molecule agonists of the AP signaling pathway - cell viability counter screen,0.2644678450750164
qHTS assay to identify small molecule agonists of the AP signaling pathway: Summary,0.5601761773312492
qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,0.5010157835969697
qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,0.23582308493050572
qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,0.43510257995541946
qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,0.8069598341355579
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,0.6482783688692737
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,0.8730960721426448
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,0.9703063153257253
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,0.7652200786669318
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,0.7058302863724802
qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,0.24449752273792819
qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,0.1912615355669889
qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,0.6144993789480334
qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,0.8871759295193706
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,0.6135674593016538
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,0.14612874354727776
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,1.0
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,0.0626557150275515
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,0.45125651209937223
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,0.6135674593016538
qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,0.028836731725951845
qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,0.20417705813300255
qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,0.034405413854623305
qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,0.2714679648995111
qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,0.1449122536569218
qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,0.202669438693548
qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,0.2224562384210616
qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,1.0
qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,0.7602422820475202
qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,1.0
qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,1.0
qHTS assay to identify small molecule agonists of the hypoxia (HIF) signaling pathway - cell viability counter screen,0.9910134558706876
qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,0.9580004860100225
qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,0.022329764599267762
qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,0.0005817229069977183
qHTS assay to identify small molecule agonists of the progesterone receptor (PR) signaling pathway,1.0
qHTS assay to identify small molecule agonists of the progesterone receptor (PR) signaling pathway - cell viability counter screen,0.07727316375300317
qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,0.022997761860409454
qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,0.13107003855419558
qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,0.16821833758279991
qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,0.34322348510193834
qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,1.0
qHTS assay to identify small molecule antagonists of the TGF-beta/Smad signaling pathway - cell viability counter screen,0.9605410446218092
qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,0.29115633314686085
qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,0.32802832998464015
qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,0.7698055645650919
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,0.21701058183572686
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,0.29235688774103014
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,0.5214890439983264
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,0.04579049033344431
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,0.025888380850585355
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,0.01680992625537129
qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,0.2664581641132898
qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,0.6710766345828965
qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,0.15681363220513403
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,0.16772024342723138
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,0.944755430239822
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,0.5172110008891069
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,0.8385113941932157
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,0.6923621917335019
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,0.5490492069901136
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,0.4994476082672932
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,0.5172110008891069
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,0.16772024342723138
qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,0.2705001615595741
qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,0.09266105289067693
qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,0.056905302793537275
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,0.00382788202229002
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,0.029769561794838674
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,0.026446125361555963
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,0.05144132309913059
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,0.612439119138184
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,0.1389622128056514
qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,0.4400750842266654
qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,0.19407119346940374
qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,0.16834142458495055
qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,0.15644227876581904
qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,0.7173816491417093
qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,0.03599567614956836
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,0.01936492731042026
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,1.0
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,1.0
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,0.6037554687874362
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,0.020109669712079902
qHTS assay to identify small molecule antagonists of the progesterone receptor (PR) signaling pathway,0.01167517994874622
qHTS assay to identify small molecule antagonists of the progesterone receptor (PR) signaling pathway - cell viability counter screen,0.07641885915529822
qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway ,0.06943694359911433
qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,0.042529507138534935
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway ,0.09133839158675429
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,1.0
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,0.052515038886083686
qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,0.004474810817194455
qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,0.11679577401673322
qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,0.7604159790576295
qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,0.030522380073039083
qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,0.5922547691385943
qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,0.01218854807563222
qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,1.0
qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,0.25711370165634906
qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,1.0
qHTS assay to identify small molecule inhibitors of chordoma cells - UCH,0.8324158355499787
qHTS assay to identify small molecule inhibitors of firefly luciferase,0.02018178298428658
qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,0.41819472008545766
qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,0.6425937683233653
qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,0.18062246621984143
qHTS for Agonists of Human Resolvin D1 Receptor DRV1,1.0
qHTS for Inhibitors of Inflammasome Signaling:  IL-beta AlphaLISA Primary Screen,0.5414072904884732
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,0.2583824446469681
qHTS for Inhibitors of Polymerase Eta,0.4152969647177993
qHTS for Inhibitors of Polymerase Iota,1.0
qHTS for Inhibitors of Polymerase Kappa,0.9518959057583539
qHTS for Inhibitors of TGF-b,0.5460886988873916
qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,0.156092340204363
"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",0.8566501407811465
qHTS for Inhibitors of binding or entry into cells for Lassa Virus,0.4125847874682439
qHTS for Inhibitors of binding or entry into cells for Marburg Virus,0.10127487718936336
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,0.4267502560857013
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,0.6173919379715466
qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen,0.21442536967959466
qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal,0.15842166092128415
qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - alamar blue signal for LCMV Primary Screen,1.0
qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT080-IDH1KD cell line,0.10534205970365779
qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT080-NT fibrosarcoma cell line,0.5693234358019281
qHTS for inhibitors of ROR gamma transcriptional activity,0.7962571310084245
qHTS of D3 Dopamine Receptor Agonist: qHTS,0.012408095083253627
qHTS of D3 Dopamine Receptor Antagonist: qHTS,0.39262777069926846
qHTS of D3 Dopamine Receptor Potentiators: qHTS,0.012408095083253627
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells,0.43100604409888355
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT2 cells,0.19039411527748548
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells,0.48758982771015813
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells,0.06164272140002237
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells,0.9359482004597455
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells,0.31754557760503854
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells,0.9386140437096766
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells,0.6705733370775773
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells,0.9269061180064642
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells,0.16319201259208715
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells,0.6036352265043481
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells,0.12753250340269184
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells,0.4456984500547425
qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),0.15987837187883594
qHTS profiling for inhibitors of Plasmodium falciparum proliferation,0.24551964593224776
uHTS Fluorescent assay for identification of inhibitors of Apaf,0.6356506573356102
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,0.9263708881725222
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,0.22667201699278175
uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,0.813881362782047
A qHTS for Small Molecule Inhibitors of Shiga Toxin,0.5216689839004323
Agonist activity at human ADRA1A in an in vitro cell-based assay (NIBR assay) measured by fluorescent imaging plate reader,1.0
Agonist activity at human ADRA2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Agonist activity at human DRD1 in an in vitro cell-based assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Agonist activity at human HTR1A in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Agonist activity at human NR1I2 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).,0.07802741398498787
Antagonist activity at human ADRA2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Antagonist activity at human CHRM2 in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Antagonist activity at human HRH1 in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Antagonist activity at human HTR1A in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Antagonist activity at human HTR2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Antagonist activity at human HTR2B in an in vitro cell-based assay measured by fluorescent imaging plate reader,1.0
Binding affinity towards human ADORA3 in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Binding affinity towards human ADRA1A in an in vitro assay with cellular components (NIBR assay) measured by scintillation proximity assay,1.0
Binding affinity towards human ADRA2B in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Binding affinity towards human ADRB2 in an in vitro assay with cellular components measured by radioactivity method,1.0
Binding affinity towards human ADRB3 in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Binding affinity towards human AGTR1 in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Binding affinity towards human CHRM3 in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Binding affinity towards human CNR1 in an in vitro assay with cellular components measured by membrane filtration,1.0
"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",1.0
Binding affinity towards human ESR1 in an in vitro cell free assay (NIBR assay) measured by fluorescence polarization method,1.0
Binding affinity towards human GHSR in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Binding affinity towards human HRH1 in an in vitro assay measured by filtration,1.0
Binding affinity towards human HRH2 in an in vitro assay with cellular components measured by membrane filtration,1.0
Binding affinity towards human HTR2A in an in vitro assay with cellular components measured by membrane filtration,1.0
Binding affinity towards human HTR2B in an in vitro assay with cellular components measured by membrane filtration,1.0
Binding affinity towards human HTR2C in an in vitro assay with cellular components measured by radioactivity method,1.0
Binding affinity towards human MC3R in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Binding affinity towards human MLNR in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
"Binding affinity towards human NR3C1 in an in vitro cell free assay measured by filtration, radioactivity method",1.0
Binding affinity towards human OPRD1 in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
"Binding affinity towards human OPRK1 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",1.0
Binding affinity towards rat Ar in an in vitro cell free assay measured by fluorescence polarization method,1.0
CCRIS mutagenicity studies,0.2410710248675293
"Compound was evaluated for inhibition of human ABCB11 in an in vitro assay with cellular components measured by filtration, liquid scintillation counting",1.0
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration,1.0
Compound was evaluated for inhibition of human ADRB1 in an in vitro assay measured by radioactivity method,1.0
Compound was evaluated for inhibition of human CHRM1 in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
"Compound was evaluated for inhibition of human HTR3A in an in vitro assay with cellular components measured by membrane filtration, radioactivity method",1.0
Compound was evaluated for inhibition of human PDE4D in an in vitro cell free assay measured by scintillation proximity assay,1.0
Compound was evaluated for inhibition of human PTGS2 in an in vitro cell free assay measured by fluorescence spectroscopy,1.0
Compound was evaluated for inhibition of rat Cacna1c in an in vitro assay with cellular components measured by membrane filtration,1.0
Compound was evaluated for inhibition of rat Gabra1 in an in vitro assay with cellular components measured by membrane filtration,1.0
Compound was evaluated for inhibition of rat Ptgs1 in an in vitro cell free assay measured by fluorescence spectroscopy,1.0
Cytotoxicity against human A549 cells after 72 hrs by MTT assay,1.0
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),1.0
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),1.0
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),1.0
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),1.0
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP2177),1.0
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),1.0
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),1.0
DRUGMATRIX: AlphaA adrenergic receptor radioligand binding (ligand: prazosin),1.0
DRUGMATRIX: AlphaB adrenergic receptor radioligand binding (ligand: prazosin),1.0
DRUGMATRIX: AlphaD adrenergic receptor radioligand binding (ligand: prazosin),1.0
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),1.0
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),1.0
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),1.0
"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",1.0
"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",1.0
"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",1.0
"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",1.0
"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",1.0
"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",1.0
"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",1.0
"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",1.0
DRUGMATRIX: Cyclooxygenase COX enzyme inhibition (substrate: Arachidonic acid),1.0
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),1.0
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),1.0
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),1.0
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),1.0
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),1.0
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),1.0
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),1.0
"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",1.0
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),1.0
"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",1.0
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),1.0
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),1.0
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),1.0
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),1.0
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),1.0
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),1.0
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),1.0
"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",1.0
"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",1.0
"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",1.0
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),1.0
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),1.0
"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",1.0
"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",1.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),1.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),1.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),1.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),1.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),1.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR13808),1.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),1.0
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),1.0
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),1.0
"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",1.0
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),1.0
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),1.0
"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",1.0
Diffuse intrinsic pontine glioma (JHH-DIPG) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,0.915089883786783
Diffuse intrinsic pontine glioma (SU-DIPG-XIII) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,0.4170702084512
Diffuse intrinsic pontine glioma (SU-DIPG-XVII) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,0.9414995533702494
Diffuse intrinsic pontine glioma (SU-DIPG-XXV) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Fluor,1.0
Diffuse intrinsic pontine glioma (SU-DIPG-XXV) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,1.0
"FDA HLAED, alkaline phosphatase increase",0.004380639879973539
"FDA HLAED, gamma-glutamyl transferase (GGT) increase",0.24403146249246793
"FDA HLAED, lactate dehydrogenase (LDH) increase",0.9439149706681949
"FDA HLAED, liver enzyme composite activity",0.000778098154959613
"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",1.4115429307349013e-05
"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",8.912969983487871e-05
Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,1.0
Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,1.0
Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,1.0
Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,1.0
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,1.0
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,1.0
Primary Screen for Target Class Profiling of Small Molecule Inhibitors of Methyltransferases,0.45002637460509376
qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary,1.0
CCRIS carcinogenicity studies,0.23567670048208741
GENE-TOX mutagenicity studies,0.004771318940714541
Agonist activity at human OPRM1 in an in vitro assay with cellular components measured by scintillation proximity assay,1.0
Agonist activity at human PGR in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Antagonist activity at human PGR in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Binding affinity towards human NR1I2 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Human mu receptor (Opioid receptors),1.0
Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,1.0
"Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)",1.0
"Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)",1.0
Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,1.0
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr,1.0
Confirmatory Screen for Target Class Profiling of Small Molecule Inhibitors of Methyltransferases,1.0
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,1.0
"DNDI: Chagas in Vitro, 96 hour",1.0
"DNDI: HAT in Vitro, 72 hour",1.0
"DNDI: Malaria in Vitro, 72 hour",1.0
"DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: ""Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.""",1.0
Diffuse intrinsic pontine glioma (JHH-DIPG) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.9712320709460726
Diffuse intrinsic pontine glioma (SU-DIPG-IV) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.4185699570087734
Diffuse intrinsic pontine glioma (SU-DIPG-VI) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.6335216090767001
Diffuse intrinsic pontine glioma (SU-DIPG-XIII) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.0238466325143774
HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,0.8215010838726202
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,0.0049507692191413655
High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,0.36168362243874264
Inhibition of CYP3A4,1.0
Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-taurocholate by topcount based membrane vesicle transport assay,1.0
Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay,1.0
Inhibition of human ERG,1.0
Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol7beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay,1.0
Inhibitor identification of human QSOX1 enzyme: high-throughput screening using HyperBlu(TM) assay,0.970273570720724
Inhibitor identification of human QSOX1 enzyme: high-throughput screening using ROS-Glo(TM) assay,0.9328205181296524
Inhibitory concentration against IKr potassium channel,1.0
Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,1.0
NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) - Blood-Brain Barrier (BBB) Permeability Screen,0.44289106991961835
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,0.06647015629793027
Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay,0.043831735638755566
"No assay is provided from Article 10.1002/med.21724: ""The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.""",0.31002239744981547
Phospholipidosis-positive literature compound observed in rat,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  AMO1_DSMZ cell viability assay,0.8479344565955256
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  ARD_JJKsccE7 cell viability assay,0.17357612118315496
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  ARP1_JJKsccF8 cell viability assay,0.5236296699501861
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  Delta47_JCRB cell viability assay,0.2492252624448708
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  EJM_DSMZ cell viability assay,0.18810874777153128
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  FR4_PLB cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  H1112_PLB cell viability assay,0.14857335733238636
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  INA6_PLB cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JIM1_ECACC cell viability assay,0.995254060737025
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JIM3_ECACC cell viability assay,0.6505921684813379
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JJN3_DSMZ cell viability assay,0.9501767143706988
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  Karpas25_ECACC cell viability assay,0.17814667740641704
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KHM11_PLB cell viability assay,0.9167099134385205
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMM1_JCRB cell viability assay,0.7440292359414968
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS12BM_JCRB cell viability assay,0.5152131956176178
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS12PE_JCRB cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS20_JCRB cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS21BM_JCRB cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS26_JCRB cell viability assay,0.6508414214126503
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS27_JCRB cell viability assay,0.48611501020625725
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS28PE_JCRB cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS34_JCRB cell viability assay,0.8581732408234761
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: Karpas417_ECACC cell viability assay,0.5252588087560615
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: Karpas620_DSMZ cell viability assay,0.6941221030049907
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: L363_DSMZ cell viability assay,0.551410183271571
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: LP1_DSMZ cell viability assay,0.5672689847453761
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MM1R_ATCC cell viability assay,0.5747122019609224
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MM1S_ATCC cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MMM1_PLB cell viability assay,0.9472825840858714
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MOLP8_DSMZ cell viability assay,0.4443037992775054
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: NCIH929_DSMZ cell viability assay,0.7680747892848732
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY1_PLB cell viability assay,1.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY5_PLB cell viability assay,0.9207285290445617
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY7_PLB cell viability assay,0.9223389720245625
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OPM1_PLB cell viability assay,0.6632460539838988
Rescue cell viability in cybrid cells with a genetic mutation in complex 1 of the mitochondria,0.179314400446332
Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,0.4560326420456019
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),0.33364008737611506
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),0.26595615095564196
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),0.8119106123003286
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),0.6722863425438572
qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,1.0
qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,0.9614703901919754
qHTS for Inhibitors of ATXN expression: Validation,0.287070661079522
qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,0.33410381016658897
qHTS for inhibitors of binding or entry into cells for Marburg Virus,0.09445488786949503
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells),1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT2 cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells,0.4090678976041089
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells,0.9066202986863585
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells,0.24025054383224842
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells,0.8367306307697281
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells,0.333812841153715
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells,0.42806644281284745
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells,0.292546605104427
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells,0.3982254899063532
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells,0.15100248726825302
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells,0.8469907141929937
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells,0.09508204063122838
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells,0.7164350076831114
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells,0.4945960197514595
96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,0.3897745469771704
Aqueous Solubility from MLSMR Stock Solutions,0.19305621822326938
BK Channel Variant Modulator Selectivity Assay,0.6550356356101141
Cell Viability - H-4-II-E,0.5756056623933539
Cell Viability - Hek293,1.0
Cell Viability - Jurkat,0.37241170169069393
Cell Viability - LYMP1-002 - Assay at 40 hr,0.2332194713640847
Cell Viability - LYMP1-003 - Assay at 40 hr,0.25548386970605946
Cell Viability - LYMP2-010,0.7597699696104405
Cell Viability - LYMP2-018,0.19268475194899565
Cell Viability - LYMP2-022,0.9286478673718206
Cell Viability - LYMP2-024,0.52777870059009
Cell Viability - N2a,0.9745209772040232
Cell Viability - NIH 3T3,0.967107781649767
Cell Viability - Renal Proximal Tubule,0.29016083374549206
Cell Viability - SH-SY5Y,0.3660610531402879
Cell Viability - SK-N-SH,0.07861283244437241
Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,0.6982353813665964
Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),1.0
Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),1.0
HTS to identify compounds that affect the blood-brain barrier permeability in vitro,0.2550756570183772
High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,0.734710987384337
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),0.8271527908095567
Human A549 Lung Tumor Cell Growth Inhibition Assay,0.7149903023071433
Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,1.0
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,0.88072145483086
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,0.583765520678903
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,1.0
Leishmania major promastigote HTS,0.9660702996935479
Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,0.3603404397988442
MDR,0.3405120647939486
MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,0.3944853446494645
MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,0.3030171598529589
MLPCN Streptokinase Expression Inhibition,0.0158606908380745
MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,0.19840519563270337
MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,0.017510117947101108
"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",1.0
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,0.9740862651017654
NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,0.1878761903042781
Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay,0.9035751925923317
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,0.9561100301693517
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,1.0
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,1.0
"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",0.5567317068981972
"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",0.9098020428687134
qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,0.2880493004503557
qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,0.8642685675536753
qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,1.0
qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,1.0
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",1.0
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",0.7900052339812336
qHTS Assay for Inhibitors of N-terminal methyltransferase 1 (NTMT1): LOPAC validation of the NTMT1 SAHH-coupled ThioGlo3 Assay,0.4571387728888082
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,0.5971939687670443
qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,0.19638739526724572
qHTS assay for small molecule activators of the p53 signaling pathway,1.0
qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,1.0
qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,0.9526257776070592
qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,0.7953128208088263
qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,0.8173489528848831
qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,0.45258707215714244
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway ,1.0
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),1.0
qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,1.0
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,0.6925403441447235
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,1.0
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,0.6460405833868256
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,0.6838005304091254
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,0.5568489731077471
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,0.5893270936610537
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,0.37258268026796826
Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,1.0
Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,1.0
Agonist activity at rat Ar in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,1.0
Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N oxygen probe based fluorescence assay,1.0
Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,1.0
Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,1.0
Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,1.0
Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,1.0
Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,1.0
Total Cmax in human administered as single dose,1.0
Unbound Cmax in human plasma,1.0
Wombat Data for BeliefDocking,1.0
384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors,0.7537128136328131
384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors,1.0
DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,0.3088511047203547
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,0.9935264582358071
DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,0.35792195723688636
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,0.052971745528488455
DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,0.20677917951810096
Furin counterscreen qHTS for Zika virus inhibitors,0.12208138042400786
NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,0.763024600552995
NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,0.6928900811071856
NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,0.8560496703118965
NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,0.969095757127322
NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,0.6538193334124995
NCI human tumor cell line growth inhibition assay. Data for the CAKI Renal cell line,0.9035230489230105
NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,0.8324280805186962
NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the DU45 Prostate cell line,0.35095298581535506
NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,0.9252344994795639
NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the HCT16 Colon cell line,0.9130177959927995
NCI human tumor cell line growth inhibition assay. Data for the HCT5 Colon cell line,0.9327174017860288
NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,0.8782751784478802
NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,0.510906289747848
NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,0.9817796963053715
NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,0.9973621213408632
NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,0.7949470705233457
NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,0.8879340986194557
NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,0.9429625208059963
NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,0.9198122218117385
NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,0.3346298837931842
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,0.8511670585540675
NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,0.8269525602232132
NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,0.5380546384519415
NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,0.7576544631928543
NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,0.9443138284713452
NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,0.7641246174159761
NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,0.9094706816196079
NCI human tumor cell line growth inhibition assay. Data for the SNB9 Central Nervous System cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,1.0
NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,0.8868289433612662
NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,0.799808348261679
NCI human tumor cell line growth inhibition assay. Data for the TK0 Renal cell line,0.5184160038379358
NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,0.8714937274447514
NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,0.798707312180073
NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,0.6887731913968347
NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,1.0
Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors,0.11670161463068326
Confirmatory qHTS to identify inhibitors of SARS-CoV-2 cell entry,1.0
Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,1.0
Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,1.0
VSVG counterscreen qHTS to identify inhibitors of SARS-CoV-2 cell entry,1.0
A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,1.0
A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,1.0
A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,1.0
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,1.0
Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,0.5671096293585215
Cell Viability Profiling of Human Lymphoblast Cell Lines,0.5067648013362416
Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors,1.0
Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors,0.0567584416259285
Cytotoxicity activity against human HepG2 cells assessed by CellTiter-Glo luminescent cell viability assay.,1.0
Decreased HeLa cell count-IC50,0.9692974190048833
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,1.0
Increased HeLa cells with 2N DNA content-IC50,0.8278169455724104
Ligands of bioamine (Class A) GPCRs,1.0
Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus,1.0
Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity,1.0
Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus,1.0
Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_CherryPick_Activity,1.0
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,0.6984664186536775
NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,0.4566357208894225
SANGER: Inhibition of human 697 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A101D cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A253 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A388 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A498 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ACN cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ATN cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BE3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BV73 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Becker cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CESS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CGTH-W cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CMK cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CTB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CTV cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DEL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DJM cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DMS14 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Daudi cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ETK cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EW cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EW1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EW3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EW6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EW8 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EoL-cell cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GAK cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GDM cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GI cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HEL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HH cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HT cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HT44 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human JAR cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human K5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KALS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KASUMI cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KGN cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KINGS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KU812 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KY821 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LS034 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LS23 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LU34-A cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LU39 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MHH-NB1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MHH-PREB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MOLT6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MV-41 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB14 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-SNU cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NH2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NKM cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NOMO cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NOS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OMC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RH cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RKO cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RS41 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SBC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SJSA cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-LMS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-MEL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-NEP cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-UT cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SR cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ST486 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SU-DHL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE0 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human no0 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human no1 cell growth in a cell viability assay.,1.0
Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,0.4078373860045268
alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,0.799639638062867
nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells,1.0
Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay,0.8612802333609997
Binding affinity towards human HTR5A in an in vitro assay with cellular components measured by membrane filtration,1.0
Binding affinity towards human HTR6 in an in vitro assay with cellular components measured by membrane filtration,1.0
Binding affinity towards human HTR7 in an in vitro assay with cellular components measured by membrane filtration,1.0
Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,1.0
Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,1.0
Experimentally measured binding affinity data derived from PDB,1.0
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,0.6465037564327235
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,0.9221191039598948
Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol7beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay,1.0
Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,0.9724160819999909
Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,0.20719856762977598
Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines,0.41593762623302233
Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines,0.881747163377889
"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A278, Adherent)",1.0
"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent)",1.0
Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose),1.0
Immunotoxin (HA22) sensitization/mitigation study - treatment arm (low dose),0.5852549914443697
Immunotoxin (HA22) sensitization/mitigation study. Vehicle arm (PBS),0.8085431871441616
Immunotoxin (SS1P) sensitization/mitigation study - treatment arm,0.8907750530055489
Immunotoxin (SS1P) sensitization/mitigation study. Vehicle arm (DMEM),0.926611028101784
NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,0.1463990992829598
NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,0.4163789567288976
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice,0.454463708770277
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,1.0
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,1.0
qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway.,1.0
qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,0.41431294850729916
A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Mycobacterium Tuberculosis,1.0
A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol,0.36382330555963893
Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,1.0
Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,0.5631709285261859
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,1.0
Colo320 viability from Cell TiterGlo-IC50,0.16849346784240632
Confirmatory qHTS for gynecologic anti-cancer compounds from libraries of approved drugs and bioactive compounds,0.4595973861839421
Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,0.9122193272812886
Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,1.0
Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,0.7100208036158184
Counterscreen for inhibitors of RecBCD: Absorbance-based cell-based high throughput assay to identify inhibitors of bacterial viability,0.9599064294462306
DLD viability from Cell TiterGlo-IC50,1.0
GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,0.5528692834745896
HCT116 viability from Cell TiterGlo-IC50,0.6791320261501701
HT-29 viability from Cell TiterGlo-IC50,0.8588071759701096
High Throughput Screening of small molecules that kill Mycobacterium tuberculosis,0.1732148014348312
Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis,1.0
RKO viability from Cell TiterGlo-IC50,0.44372565284439414
Rucaparib conditional oncology-focused drug screen on ovarian cancer cells.,1.0
SNU-C1 viability from Cell TiterGlo-IC50,1.0
SW480 viability from Cell TiterGlo-IC50,0.7879416511227975
VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,0.31514846221514276
Binding affinity towards human CHRM5 in an in vitro assay with cellular components measured by membrane filtration,1.0
Binding affinity towards human DRD4 in an in vitro assay with cellular components measured by membrane filtration,1.0
Binding affinity towards human TACR1 in an in vitro assay with cellular components measured by membrane filtration,1.0
Compound was evaluated for inhibition of human SCN5A in an in vitro cell-based assay measured by IonWorks automated patch clamp,1.0
Human H1 receptor (Histamine receptors),1.0
Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,1.0
Inhibition of human Potassium channel HERG expressed in mammalian cells,1.0
Inhibitory concentration against potassium channel HERG,1.0
Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,1.0
Human D1 receptor (Dopamine receptors),1.0
Human D2 receptor (Dopamine receptors),1.0
Human D3 receptor (Dopamine receptors),1.0
Human D4 receptor (Dopamine receptors),1.0
Human D5 receptor (Dopamine receptors),1.0
Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,1.0
Compound was evaluated for inhibition of rat Slc18a2 in an ex vivo assay measured by radioactivity method,1.0
Confirmatory qHTS for activators (rescue) of SARS-CoV-2 Cytopathic Effect (CPE),1.0
Human 5-HT2B receptor (5-Hydroxytryptamine receptors),1.0
Human SERT (Monoamine transporter subfamily),1.0
Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,1.0
Mouse Kir3.2 (Inwardly rectifying potassium channels),1.0
Rat 5-HT2A receptor (5-Hydroxytryptamine receptors),1.0
Rat 5-HT6 receptor (5-Hydroxytryptamine receptors),1.0
DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity,0.923724918398048
Human COX  (Cyclooxygenase),1.0
Human COX-2  (Cyclooxygenase),1.0
Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay,1.0
Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,1.0
Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,1.0
Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,1.0
Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,1.0
Cytotoxicity against human A549 cells after 48 hrs by MTT assay,1.0
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,1.0
Ligands of peptide (Class A) GPCRs,1.0
Solubility by shake flask method,1.0
Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,1.0
NCATS Kinetic Aqueous Solubility Profiling,0.8474858238624419
NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling,1.0
NCATS Rat Liver Microsome Stability Profiling,0.8787003779972211
Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days,1.0
Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay,1.0
Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy,1.0
Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,1.0
Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,1.0
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,1.0
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,1.0
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,1.0
Cmax in human,1.0
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,1.0
NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,0.9543432001989234
SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 5637 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 639-V cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 647-V cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 769-P cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 8305C cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human 8505C cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A172 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A204 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A2058 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A2780 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A427 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A431 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A673 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human A704 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ABC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ACHN cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human AU565 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BHY cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BPH cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human C3A cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAKI cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAL2T cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CAPAN cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CHL cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ChaGo-K cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DU45 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Daoy cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EFM9 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human EGI cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ESS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human FADU cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human FTC33 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human G-401 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human G-402 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GAMG cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GCT cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human GP5d cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human H4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HCT16 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HEC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HLE cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HN cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HO-N cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HOS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HT376 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HuO-3N1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human J82 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KLE cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KYSE40 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KYSE80 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LCLC03H cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LK-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LU-99A cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human LoVo cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human M14 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MDA-MB-415 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human ME80 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MHH-ES cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MKN28 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human Mewo cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H28 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human NY cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OE33 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PA cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PANC0-05 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PC4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PC-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human PFSK cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RCM cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RD cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human RT12 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human S17 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SAS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SCC5 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SF295 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-HEP cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-LU cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SK-MES cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SN12C cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW1088 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW13 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW48 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW620 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW756 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human SW982 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human T98G cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TE1 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human VM-CUB cell growth in a cell viability assay.,1.0
Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,0.47085960571294017
Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,0.9033931946122046
Compound was evaluated for inhibition of human CACNA1C in an in vitro cell-based assay measured by IonWorks automated patch clamp,1.0
Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),1.0
"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta subunits",1.0
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,1.0
Inhibition of hERG K channel,1.0
Antiviral activity against HIV1,1.0
Cytotoxicity against human HeLa cells,1.0
Confirmatory qHTS for inhibitors of MERS-S pseudo-typed particle cell entry,0.7926825815887464
Confirmatory qHTS for inhibitors of SARS-S pseudo-typed particle cell entry,0.9038799668928443
VSV-G qHTS counterscreen for inhibitors of MERS-S pseudo-typed particle cell entry,0.4298599282452711
VSV-G qHTS counterscreen for inhibitors of SARS-S pseudo-typed particle cell entry,1.0
Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test,1.0
Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test,1.0
Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid,1.0
Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid,1.0
Human 5-HT6 receptor (5-Hydroxytryptamine receptors),1.0
Human M1 receptor (Acetylcholine receptors (muscarinic)),1.0
Human M2 receptor (Acetylcholine receptors (muscarinic)),1.0
Human M3 receptor (Acetylcholine receptors (muscarinic)),1.0
Human M4 receptor (Acetylcholine receptors (muscarinic)),1.0
Human NET (Monoamine transporter subfamily),1.0
Inhibition of human ERG in MCF7 cells,1.0
Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state,1.0
K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,1.0
Rat 5-HT7 receptor (5-Hydroxytryptamine receptors),1.0
Human DAT (Monoamine transporter subfamily),1.0
SANGER: Inhibition of human 23132-87 cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human AGS cell growth in a cell viability assay.,1.0
SANGER: Inhibition of human IGROV cell growth in a cell viability assay.,1.0
Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient,1.0
Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient,1.0
Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient,1.0
Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient,1.0
Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient,1.0
Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient,1.0
Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,1.0
Human 5-HT1A receptor (5-Hydroxytryptamine receptors),1.0
Human 5-HT2A receptor (5-Hydroxytryptamine receptors),1.0
Human 5-HT2C receptor (5-Hydroxytryptamine receptors),1.0
Human 5-HT7 receptor (5-Hydroxytryptamine receptors),1.0
Human alpha2A-adrenoceptor (Adrenoceptors),1.0
Human alpha2B-adrenoceptor (Adrenoceptors),1.0
Human alpha2C-adrenoceptor (Adrenoceptors),1.0
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,1.0
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,1.0
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,1.0
Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,1.0
"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",1.0
"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",1.0
Inhibition of human cytochrome P450 3A4,1.0
TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,1.0
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,1.0
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, ratio channel",0.5515465854166592
qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation,0.4273553138978078
Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,1.0
Inhibition of DR24 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis,1.0
Confirmatory qHTS for antagonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2),0.18395430218086994
Inhibition of cigarette smoke extract (CSE) and LPS-stimulated mouse B cell migration at 1 uM relative to control,1.0
Inhibition of human BSEP expressed in HEK293 cell membrane vesicles assessed as reduction in 3H-TCA uptake incubated for 5 mins by radiodetection method,1.0
"3H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: ""The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.""",1.0
Human alpha1D-adrenoceptor (Adrenoceptors),1.0
Human beta1-adrenoceptor (Adrenoceptors),1.0
Human beta2-adrenoceptor (Adrenoceptors),1.0
Confirmation assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytes,1.0
Confirmation qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),0.5509849875850935
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells,1.0
A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,1.0
A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhimurium identified in the primary screen,1.0
A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen.,1.0
Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay,1.0
Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay,1.0
Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay,1.0
Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,1.0
Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay,1.0
Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay,1.0
Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay,1.0
Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay,1.0
Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,1.0
Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis,1.0
Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay,1.0
Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay,1.0
Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay,1.0
Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis,1.0
Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay,1.0
Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay,1.0
Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay,1.0
Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay,1.0
Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay,1.0
Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay,1.0
Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,1.0
Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay,1.0
Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay,1.0
Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay,1.0
Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay,1.0
Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay,1.0
Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay,1.0
Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay,1.0
Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method,1.0
Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,1.0
Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay,1.0
Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay,1.0
Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay,1.0
Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay,1.0
Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay,1.0
Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay,1.0
Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs,1.0
Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,1.0
Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A,1.0
Human 5-HT1B receptor (5-Hydroxytryptamine receptors),1.0
Human 5-HT1D receptor (5-Hydroxytryptamine receptors),1.0
Human alpha1A-adrenoceptor (Adrenoceptors),1.0
Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F,1.0
Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e,1.0
Human 5-HT1F receptor (5-Hydroxytryptamine receptors),1.0
Human 5-ht1e receptor (5-Hydroxytryptamine receptors),1.0
Inhibition of human ERG channel,1.0
Human alpha1B-adrenoceptor (Adrenoceptors),1.0
Human delta receptor (Opioid receptors),1.0
Human kappa receptor (Opioid receptors),1.0
Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay,1.0
